Altana's Non-Venture Fund
This article was originally published in Start Up
Altana AG has set up an investment fund which will focus on deals to support its pharmaceuetical business (Byk Gulden) by making technology-based investments through deals with biotech companies.
You may also be interested in...
A few of Europe's mid-sized drug companies are trying to exploit the advantages of venture investing through in-house venture funds. Success, so far, has been elusive.
The success of gastrointestinal drug pantoprazole has turned mid-sized Altana into one of Europe's fastest growing pharmaceutical companies. By re-investing the proceeds from pantoprazole into its own R&D, Altana now has two late-stage follow-ons--ciclesonide and roflumilast--with similar potential to pantoprazole. Rather than simply out-licensing these compounds to larger players, Altana wants a more active role alongside its partners in marketing and selling its own drugs, hoping thereby to establish itself internationally.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.